Imagenomix, an NYU Langone spinout developing AI-driven cancer diagnostics from standard histopathology images, raised $3.2 million in seed funding. The company said it uses AI to detect genetic alterations directly from tissue slides and map spatial mutation distribution without requiring sequencing. Imagenomix plans to use the financing to initiate a clinic trial in breast cancer and to commercialize a V2 lung cancer classifier later in 2026 in collaboration with digital pathology firm Proscia. The company also intends to support its alliance with Alterome Therapeutics, where its platform is being used in Phase I studies for precision oncology candidates. The seed round was led by Modi Ventures with participation from NYU Langone Venture Fund and other named venture vehicles, highlighting continued investment in image-to-genomics approaches for molecular-grade decision support.